8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF
1934
Date
of Report (Date of earliest event reported): August 13, 2018
VistaGen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
NEVADA
|
001-37761
|
20-5093315
|
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification Number)
|
|
343 Allerton Ave.
South San Francisco, California 94090
|
|
(Address of principal executive offices)
|
(650) 577-3600
(Registrant’s telephone number, including area
code)
Not Applicable
(Former name or former address, if changed since last
report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities
Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR 240.12b-2) ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act ☐
On August 13, 2018, VistaGen Therapeutics, Inc.
(the “Company”) and Baylor College of Medicine
(“Baylor”) announced that the Company and Baylor are
collaborating on a first-step study with healthy volunteer Veterans
to test potential anti-suicidal effects of AV-101, the
Company’s oral CNS drug candidate. The Company will provide
the clinical trial material for this study, and government funding
will be provided for substantially all other study costs. AV-101 is
in Phase 2 clinical development in the United States as an
adjunctive treatment of Major Depressive Disorder in patients with
an inadequate response to current antidepressants approved by the
U.S. Food and Drug Administration. A copy of the Company’s
press release is attached to this Current Report on Form 8-K as
Exhibit 99.1 and is incorporated by reference
herein.
Item 9.01
Financial Statements and
Exhibits.
See
Exhibit Index.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
|
VistaGen
Therapeutics, Inc.
|
|
|
|
|
|
Date: August
14, 2018
|
By:
|
/s/ Shawn K. Singh
|
|
|
|
Shawn K.
Singh
Chief Executive
Officer
|
EXHIBIT INDEX
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
|
|
Press Release
issued by VistaGen Therapeutics, Inc., dated August 13,
2018
|